Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014 (2014), Article ID 683757, 5 pages
http://dx.doi.org/10.1155/2014/683757
Research Article

The Angiogenic Activity of Ascites in the Course of Ovarian Cancer as a Marker of Disease Progression

1Department of Gynecological Oncology and Oncology, Medicover Hospital, Rzeczypospolitej 5, 02-972 Warsaw, Poland
2Department of Obstetrics and Gynecology, Institute of Mother and Child, Kasprzaka 17A, 01-211 Warsaw, Poland
3Department of General and Experimental Pathology, Warsaw Medical University, Pawińskiego 3C, 02-106 Warsaw, Poland
4Department of Pathology, Centre of Biostructure Research, Warsaw Medical University, Chałubińskiego 5, 02-004 Warsaw, Poland
5Department of Applied Pharmacy and Bioengineering, Warsaw Medical University, Warsaw, Poland
6Institute of Mother and Child, Kasprzaka 17A, 01-211 Warsaw, Poland
71st Department of Obstetrics and Gynecology, Warsaw Medical University, Pl. Starynkiewicza 1, 02-015 Warsaw, Poland
8Department of Surgical Oncology, Holy Family Hospital, Madalińskiego 25, 02-544 Warsaw, Poland
9Department of Oncology, National Institute of Oncology, Wawelska 15, 02-034 Warsaw, Poland
10Department of Histology and Embryology, Centre of Biostructure Research, Warsaw Medical University, Chałubińskiego 5, 02-004 Warsaw, Poland

Received 27 June 2013; Revised 15 October 2013; Accepted 21 October 2013; Published 23 January 2014

Academic Editor: Natacha Turck

Copyright © 2014 Krzysztof Gawrychowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Makris, K. J. Ryan, and T. Yasumizu, “The nonluteal porcine ovary as a source of angiogenic activity,” Endocrinology, vol. 115, no. 5, pp. 1672–1677, 1984. View at Google Scholar · View at Scopus
  2. B. R. Kamat, L. F. Brown, E. J. Manseau, D. R. Senger, and H. F. Dvorak, “Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells: role in corpus luteum development,” American Journal of Pathology, vol. 146, no. 1, pp. 157–165, 1995. View at Google Scholar · View at Scopus
  3. C. G. Ioannides, C. D. Platsoucas, S. Rashed, J. T. Wharton, C. L. Edwards, and R. S. Freedman, “Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites,” Cancer Research, vol. 51, no. 16, pp. 4257–4265, 1991. View at Google Scholar · View at Scopus
  4. B. Sheid, “Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer,” Cancer Letters, vol. 62, no. 2, pp. 153–158, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Nagy, E. M. Masse, K. T. Herzberg et al., “Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation,” Cancer Research, vol. 55, no. 2, pp. 360–368, 1995. View at Google Scholar · View at Scopus
  6. P. J. van Diest, J. P. Zevering, L. C. Zevering, and J. P. A. Baak, “Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients,” Pathology Research and Practice, vol. 191, no. 1, pp. 25–30, 1995. View at Google Scholar · View at Scopus
  7. P. M. Biselli-Chicote, A. R. Oliveira, E. C. Pavarino, and E. M. Goloni-Bertollo, “VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 3, pp. 363–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Koch and L. Claesson-Welsh, “Signal transduction by vascular endothelial growth factor receptors,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 7, Article ID 006502, 2012. View at Publisher · View at Google Scholar
  9. R. M. Strieter, P. J. Polverini, D. A. Arenberg, and S. L. Kunkel, “The role of CXC chemokines as regulators of angiogenesis,” Shock, vol. 4, no. 3, pp. 155–160, 1995. View at Google Scholar · View at Scopus
  10. A. E. Koch, P. J. Polverini, S. L. Kunkel et al., “Interleukin-8 as a macrophage-derived mediator of angiogenesis,” Science, vol. 258, no. 5089, pp. 1798–1801, 1992. View at Google Scholar · View at Scopus
  11. D. Szukiewicz, M. Pyzlak, J. Klimkiewicz, G. Szewczyk, and D. Maslinska, “Mast cell-derived interleukin-8 may be involved in the ovarian mechanisms of follicle growth and ovulation,” Inflammation Research, vol. 56, no. 1, pp. S35–S36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. A. Sidky and R. Auerbach, “Lymphocyte induced angiogenesis: a quantitative and sensitive assay of the graft vs. host reaction,” Journal of Experimental Medicine, vol. 141, no. 5, pp. 1084–1100, 1975. View at Google Scholar · View at Scopus
  13. C. Y. Li, S. Shan, Q. Huang et al., “Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models,” Journal of the National Cancer Institute, vol. 92, no. 17, pp. 1445–1446, 2000. View at Google Scholar · View at Scopus
  14. A. C. Ziogas, N. G. Gavalas, M. Tsiatas et al., “VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2,” International Journal of Cancer, vol. 130, no. 4, pp. 857–864, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. E. Koch, P. J. Polverini, S. L. Kunkel et al., “Interleukin-8 as a macrophage-derived mediator of angiogenesis,” Science, vol. 258, no. 5089, pp. 1798–1801, 1992. View at Google Scholar · View at Scopus
  16. I. Matte, D. Lane, C. Laplante, C. Rancourt, and A. Piché, “Profiling of cytokines in human epithelial ovarian cancer ascites,” American Journal of Cancer Research, vol. 2, no. 5, pp. 566–580, 2012. View at Google Scholar
  17. D. Lane, I. Matte, C. Rancourt, and A. Piché, “Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients,” BMC Cancer, vol. 11, article 210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. J. Perren, A. M. Swart, J. Pfisterer et al., “A phase 3 trial of bevacizumab in ovarian cancer,” The New England Journal of Medicine, vol. 365, no. 26, pp. 2484–2496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Aghajanian, S. V. Blank, B. A. Goff et al., “OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2039–2045, 2012. View at Publisher · View at Google Scholar